Vir Biotechnology, Inc. (VIR)
$11.70+5.22%Close
BUYBULL · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.0B
- Beta
- 1.59
- P/E (TTM)
- -6.27
- Short % float
- 11.63%
- Days to cover
- 7.0
- SI change
- -23.8%
- 1W
- +4.74%
- 1M
- +10.59%
- vs SPY 1W
- +3.58%
- vs SPY 1M
- +7.59%
Industry peers
FMP comparable companies · ranked by market cap
- MRNABUYModerna, Inc.$78.0BRECOVERYQ 36$196.48+14.21%
- BNTXSELLBioNTech SE$23.9BRECOVERYQ 35$95.25+5.32%
- BCRXSELLBioCryst Pharmaceuticals, Inc.$2.1BRECOVERYQ 6$8.40+3.14%
- NVAXBUYNovavax, Inc.$1.8BRECOVERYQ 10$11.22+15.80%
- ABUSSELLArbutus Biopharma Corp$847MCRISISQ 13$4.29+0.96%
- VALNSELLValneva SE$557MCRISISQ -0$5.87+1.58%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on VIR?
- LOPJLB’s latest quantitative signal on Vir Biotechnology, Inc. (VIR) is BUY in a BULL regime. Signals are updated daily.
- What market regime is VIR in?
- Vir Biotechnology, Inc. (VIR) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Vir Biotechnology, Inc. (VIR) do?
- Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VI…